DBV Technologies (DBVT) Projected to Post Quarterly Earnings on Friday

DBV Technologies (NASDAQ:DBVT) is projected to post its Q4 2025 results before the market opens on Friday, April 10th. Analysts expect the company to announce earnings of ($0.1564) per share and revenue of $1.0890 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, April 2, 2026 at 7:00 AM ET.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings results on Saturday, February 14th. The company reported ($1.15) earnings per share (EPS) for the quarter. The business had revenue of $0.65 million for the quarter. DBV Technologies had a negative return on equity of 189.17% and a negative net margin of 2,606.83%. On average, analysts expect DBV Technologies to post $-7 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

DBV Technologies Price Performance

DBV Technologies stock opened at $21.06 on Friday. The stock has a market capitalization of $1.17 billion, a PE ratio of -4.03 and a beta of -0.94. The business has a 50 day simple moving average of $21.49 and a 200-day simple moving average of $17.53. DBV Technologies has a 12 month low of $6.00 and a 12 month high of $26.18.

Hedge Funds Weigh In On DBV Technologies

Institutional investors and hedge funds have recently bought and sold shares of the business. Ikarian Capital LLC acquired a new stake in DBV Technologies in the 4th quarter valued at about $10,064,000. Vestal Point Capital LP purchased a new position in DBV Technologies in the 4th quarter worth approximately $5,751,000. Squadron Capital Management LLC acquired a new position in shares of DBV Technologies during the 4th quarter worth approximately $4,601,000. Millennium Management LLC grew its position in shares of DBV Technologies by 89.7% in the fourth quarter. Millennium Management LLC now owns 640,885 shares of the company’s stock valued at $12,286,000 after purchasing an additional 303,022 shares in the last quarter. Finally, Engineers Gate Manager LP purchased a new stake in shares of DBV Technologies in the fourth quarter valued at approximately $479,000. 71.74% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Cantor Fitzgerald set a $48.00 price target on shares of DBV Technologies in a research note on Wednesday, December 17th. HC Wainwright set a $40.00 price objective on shares of DBV Technologies in a research report on Thursday, December 18th. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of DBV Technologies in a research report on Monday, December 29th. Finally, Guggenheim reissued a “buy” rating and set a $51.00 target price on shares of DBV Technologies in a research note on Friday, March 27th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $38.65.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.